Johns Hopkins ABX Guide
Dalbavancin
INDICATIONS
FDA
FDA
- Treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive organism.
- S. aureus(including MRSA), S. pyogenes, S. agalactiae, S. dysgalactiae, S. anginosus group, E. faecalis (vancomycin-susceptible)
NON-FDA APPROVED USES
NON-FDA APPROVED USES
No data on the use of dalbavancin for other infections, e.g., S. aureus infections (pneumonia, bacteremia, endocarditis)
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: January 30, 2017
Citation
Dzintars, Kathryn, and Paul Pham. "Dalbavancin." Johns Hopkins ABX Guide, The Johns Hopkins University, 2017. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540645/all/Dalbavancin.
Dzintars K, Pham P. Dalbavancin. Johns Hopkins ABX Guide. The Johns Hopkins University; 2017. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540645/all/Dalbavancin. Accessed December 6, 2023.
Dzintars, K., & Pham, P. (2017). Dalbavancin. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540645/all/Dalbavancin
Dzintars K, Pham P. Dalbavancin [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2017. [cited 2023 December 06]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540645/all/Dalbavancin.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Dalbavancin
ID - 540645
A1 - Dzintars,Kathryn,Pharm.D., BCPS
AU - Pham,Paul,Pharm.D.
Y1 - 2017/01/30/
BT - Johns Hopkins ABX Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540645/all/Dalbavancin
PB - The Johns Hopkins University
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
